Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas

被引:1
|
作者
Lo, Yu Tung [1 ,2 ]
Ang, Ya Lyn Samantha [1 ,2 ]
Yang, Valerie Shiwen [3 ,4 ]
Kanavathy, Dave Thevandiran [2 ]
Liang, Sai [1 ]
Lee, Lester [1 ,2 ,5 ]
机构
[1] Natl Neurosci Inst, Dept Neurosurg, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
[2] Dept Neurosurg, Outram Rd, Singapore 169608, Singapore
[3] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore
[4] Inst Mol & Cell Biol, Translat Precis Oncol Lab, A STAR, Singapore, Singapore
[5] Duke NUS Med Sch, Singapore, Singapore
关键词
PCNSL; Lymphoma; Brain biopsy; Motor recovery; Prognosis; PRIMARY CNS LYMPHOMA; INTERNATIONAL EXTRANODAL LYMPHOMA; WHOLE-BRAIN RADIOTHERAPY; HIGH-DOSE METHOTREXATE; QUALITY-OF-LIFE; PROGNOSTIC-FACTORS; UNITED-STATES; DIAGNOSIS; TUMORS; IMMUNOCHEMOTHERAPY;
D O I
10.1007/s11060-020-03665-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Central nervous system lymphomas (CNSL) can present with motor and non-motor symptoms. In many central nervous system tumors, motor deficits are associated with significant morbidity and functional impairment, and correlate with worse prognosis. CNSLs however, often exhibit remarkable response to chemotherapy and radiotherapy with corresponding symptom improvement. We investigate the survival outcomes and trajectories of motor and functional recovery in a cohort of patients presenting with and without initial motor deficits. Methods Patients who underwent biopsy and with a histologically confirmed CNSL between 2008 and 2019 were retrospectively identified. Baseline demographic variables, comorbidities, presenting symptoms, histological type, neuroimaging features (location and number of lesions), and treatment administered (pre- and post-operative steroid use and chemotherapy regime) were recorded. Dates of death were obtained from the National Registry of Births and Deaths. Motor power and performance status at admission, 1 month and 6 months were determined. Results We identified 119 patients, of whom 34% presented with focal motor deficits. The median overall survival (OS) was 26.6 months. Those with focal motor deficits had longer OS (median 42.4 months) than those without (median 23.3 months; p = 0.047). In multivariate Cox analysis, age (HR 1.04 per year; p = 0.003), CCI (HR 1.31 per point; p < 0.001), leptomeningeal/ependymal involvement (HR 2.53; p = 0.016), thalamus involvement (HR 0.34; p = 0.019), neutrophil:lymphocyte ratio (HR 1.06 per point; p = 0.034), positive HIV status (HR 5.31; p = 0.003), preoperative steroids use (HR 0.49; p = 0.018), postoperative high-dose steroids (HR 0.26; p < 0.001) and postoperative low-dose steroids (HR 0.28; p = 0.010) were significant predictors of OS. By one month, 43% of surviving patients had full power, increasing to 61% by six months. Conclusion A significant proportion of patients with initial motor deficits recovered in motor strength by six months. In our population, those presenting with motor deficits had paradoxically better overall survival.
引用
收藏
页码:295 / 306
页数:12
相关论文
共 50 条
  • [1] Motor deficits at presentation and predictors of overall survival in central nervous system lymphomas
    Yu Tung Lo
    Ya Lyn Samantha Ang
    Valerie Shiwen Yang
    Dave Thevandiran Kanavathy
    Sai Liang
    Lester Lee
    Journal of Neuro-Oncology, 2021, 151 : 295 - 306
  • [2] Central nervous system lymphomas-Assessment and treatment and prevention of central nervous system relapse
    Ghione, Paola
    Lewis, Katharine L.
    Bobillo, Sabela
    Nayak, Laksmi
    Schorb, Elisabeth
    Nichielli, Lucia
    Ng, Andrea
    Savage, Kerry J.
    McKay, Pam
    Nastoupil, Loretta
    Soussain, Carole
    Cwynarski, Kate
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [3] Primary Central Nervous System Lymphomas
    Chukwueke, Ugonma
    Grommes, Christian
    Nayak, Lakshmi
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (01) : 147 - 159
  • [4] Progress in central nervous system lymphomas
    Wang, Chia-Ching
    Carnevale, Julia
    Rubenstein, James L.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 311 - 325
  • [5] Socioeconomic deprivation and survival outcomes in primary central nervous system lymphomas
    Deng, Xiangyang
    Yang, Xionggang
    Yang, Chunlei
    Chen, Kezhu
    Ren, Junwei
    Zeng, Jun
    Zhang, Quan
    Li, Tianwen
    Tang, Qisheng
    Zhu, Jianhong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Craniotomy and Survival for Primary Central Nervous System Lymphoma
    Rae, Ali I.
    Mehta, Amol
    Cloney, Michael
    Kinslow, Connor J.
    Wang, Tony J. C.
    Bhagat, Govind
    Canoll, Peter D.
    Zanazzi, George J.
    Sisti, Michael B.
    Sheth, Sameer A.
    Connolly, E. Sander
    McKhann, Guy M.
    Bruce, Jeffrey N.
    Iwamoto, Fabio M.
    Sonabend, Adam M.
    NEUROSURGERY, 2019, 84 (04) : 935 - 943
  • [7] Rare central nervous system lymphomas
    Kaji, Furqaan Ahmed
    Martinez-Calle, Nicolas
    Sovani, Vishakha
    Fox, Christopher Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 (06) : 662 - 678
  • [8] Primary central nervous system lymphomas - Incidence and survival in the southern and eastern Netherlands
    van der Sanden, GAC
    Schouten, LJ
    van Dijck, JAAM
    van Andel, JP
    van der Maazen, RWM
    Coebergh, JWW
    CANCER, 2002, 94 (05) : 1548 - 1556
  • [9] Impact of Systemic and Radiation Therapy on Survival of Primary Central Nervous System Lymphoma
    Janopaul-Naylor, James Robert
    Patel, Jimmy S.
    Rupji, Manali
    Hoang, Kimberly Bojanowski
    Mccall, Neal Sean
    Qian, David C.
    Shoaf, Madison Lee
    Kothari, Shawn
    Olson, Jeffrey J.
    Shu, Hui-Kuo G.
    Voloschin, Alfredo
    Zhong, Jim
    Neill, Stewart G.
    Eaton, Bree
    CANCERS, 2025, 17 (04)
  • [10] Primary central nervous system lymphomas (PCNSL):: MRI features at presentation in 100 patients
    Küker, W
    Nägele, T
    Korfel, A
    Heckl, S
    Thiel, E
    Bamberg, M
    Weller, M
    Herrlinger, U
    JOURNAL OF NEURO-ONCOLOGY, 2005, 72 (02) : 169 - 177